Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cabergoline.

A Colao1, G Lombardi, L Annunziato

  • 1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy. colao@unina.it

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.

Endocrine·2026
Same author

The management of adrenocortical carcinoma in the era of precision medicine.

Critical reviews in oncology/hematology·2025
Same author

Nutritional assessment and medical dietary therapy for management of obesity in patients with non-dialysis chronic kidney disease: a practical guide for endocrinologist, nutritionists and nephrologists. A consensus statement from the Italian society of endocrinology (SIE), working group of the club nutrition-hormones and metabolism; the Italian society of nutraceuticals (SINut), club ketodiets and nutraceuticals "KetoNut-SINut"; and the Italian society of nephrology (SIN).

Journal of endocrinological investigation·2024
Same author

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.

Journal of endocrinological investigation·2024
Same author

Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism.

Journal of endocrinological investigation·2024
Same author

Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.

Journal of endocrinological investigation·2024
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Cabergoline (CAB) is a potent dopamine D2 receptor agonist that effectively suppresses prolactin secretion. It demonstrates superior efficacy and tolerability compared to bromocriptine for hyperprolactinemic disorders.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Prolactin (PRL) hypersecretion is a common endocrine disorder.
  • Dopamine agonists are the primary treatment for hyperprolactinemia.
  • Bromocriptine, a traditional dopamine agonist, has limitations in efficacy and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Cabergoline (CAB) in treating hyperprolactinemic disorders.
  • To compare CAB's effectiveness against bromocriptine.

Main Methods:

  • In vitro receptor binding studies to assess CAB's affinity and selectivity for dopamine D2 receptors.
  • In vivo studies in women with hyperprolactinemia to assess CAB's dose-dependent PRL suppression.
  • Clinical trials comparing CAB and bromocriptine in terms of biochemical response, clinical efficacy, tolerability, and tumor shrinkage.

Related Experiment Videos

Main Results:

  • Cabergoline exhibits high affinity and selectivity for dopamine D2 receptors, with potent and long-lasting inhibition of prolactin secretion.
  • CAB demonstrated significantly greater efficacy than bromocriptine in normalizing PRL levels and achieving clinical improvement.
  • CAB was better tolerated than bromocriptine, with notable tumor shrinkage observed in patients with macroprolactinoma.

Conclusions:

  • Cabergoline is a highly effective and well-tolerated treatment for hyperprolactinemic disorders, representing a preferred therapeutic option.
  • CAB shows promise in managing bromocriptine-resistant cases and other pituitary adenomas, though further research is needed.